The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
Open accessAbstract
Immunoglobulin A (IgA) is the most abundant antibody class present at mucosal surfaces. The production of IgA exceeds the production of all other antibodies combined, supporting its prominent role in host-pathogen defense. IgA closely interacts with the intestinal microbiota to enhance its diversity, and IgA has a passive protective role via immune exclusion. Additionally, inhibitory ITAMi signaling via the IgA Fc receptor (FcαRI; CD89) by monomeric IgA may play a role in maintaining homeostatic conditions. By contrast, IgA immune complexes (e.g., opsonized pathogens) potently activate immune cells via cross-linking FcαRI, thereby inducing pro-inflammatory responses resulting in elimination of pathogens. The importance of IgA in removal of pathogens is emphasized by the fact that several pathogens developed mechanisms to break down IgA or evade FcαRI-mediated activation of immune cells. Augmented or aberrant presence of IgA immune complexes can result in excessive neutrophil activation, potentially leading to severe tissue damage in multiple inflammatory, or autoimmune diseases. Influencing IgA or FcαRI-mediated functions therefore provides several therapeutic possibilities. On the one hand (passive) IgA vaccination strategies can be developed for protection against infections. Furthermore, IgA monoclonal antibodies that are directed against tumor antigens may be effective as cancer treatment. On the other hand, induction of ITAMi signaling via FcαRI may reduce allergy or inflammation, whereas blocking FcαRI with monoclonal antibodies, or peptides may resolve IgA-induced tissue damage. In this review both (patho)physiological roles as well as therapeutic possibilities of the IgA-FcαRI axis are addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease
Palm, N. W., de Zoete, M. R., Cullen, T. W., Barry, N. A., Stefanowski, J., Hao, L., Degnan, P. H., Hu, J., Peter, I., Zhang, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.006 · Cited by 1,286
Structure and function relationships in IgA
Woof, J. M., & Russell, M. W. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.39 · Cited by 367
Herremans, T. M. P. T., Reimerink, J. H. J., Buisman, A. M., Kimman, T. G., & Koopmans, M. P. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.5011 · Cited by 149
Hansen, I. S., Hoepel, W., Zaat, S. A. J., Baeten, D. L. P., & den Dunnen, J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700883 · Cited by 69
LANG, M. L., CHEN, Y.-W., SHEN, L., GAO, H., LANG, G. A., WADE, T. K., & WADE, W. F. (2002) · Biochemical Journal · doi:10.1042/bj20011696 · Cited by 60
Cited by
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA
Chen, K., Magri, G., Grasset, E. K., & Cerutti, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0261-1 · Cited by 336
The Role of Antibody Testing for SARS-CoV-2: Is There One?
Theel, E. S., Slev, P., Wheeler, S., Couturier, M. R., Wong, S. J., & Kadkhoda, K. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00797-20 · Cited by 305
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Metadata
- Authors
- Breedveld, A., & van Egmond, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-22
- Volume
- 10
- Pages
- 553-553
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2919865128
- Cited by
- 237
- References
- 5
- FWCI
- 16.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. https://app.cochat.ai/papers/10.3389/fimmu.2019.00553
- The paper
- Breedveld, A., & van Egmond, M. (2019). IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.00553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.